1. Is CD30 (Ki-1) immunostaining in cutaneous eruptions useful as a marker of Th1 to Th2 cytokine switching and/or as a marker of advanced HIV-1 disease?
- Author
-
Terry L. Barrett, Ronald C. Neafie, K.J. Smith, Tomaszewski Mm, Wagner Kf, Yeager J, H. Skelton, and Ann Marie Nelson
- Subjects
Pathology ,medicine.medical_specialty ,CD30 ,Lymphocyte ,CD3 ,medicine.medical_treatment ,Ki-1 Antigen ,Leishmaniasis, Cutaneous ,Dermatitis ,HIV Infections ,Dermatology ,Th2 Cells ,Immunopathology ,Leprosy ,medicine ,Humans ,biology ,Th1 Cells ,CD4 Lymphocyte Count ,medicine.anatomical_structure ,Cytokine ,Immunology ,biology.protein ,Disease Progression ,HIV-1 ,Cytokines ,Viral disease ,Antibody ,Immunostaining ,Biomarkers - Abstract
CD30 is a member of the tumour necrosis factor/nerve growth factor receptor superfamily, which is expressed on CD4 + and CD8 + T-cell clones which produce T helper (Th) 2-type cytokines. It has been proposed that disease progression in HIV-1 is associated with Th1 to Th2 cytokine switching. In 70 cutaneous biopsies from HIV-1 positive patients in different stages of disease, we performed a battery of immunohistochemical stains. These included antibodies to CD3, UCHL-1, OPD-4, L-26, KP-1 and CD30 (Ki-1). In addition, we used a similar battery of stains on cutaneous biopsies of HIV-1 negative patients with inflammatory dermatoses which are established as Th1 or Th2 dominant, e.g. polar leprosy. CD30 + cells were rarely present in early stages of HIV-1 disease, but commonly present in later stages of disease. However, there were cases of late HIV-1 disease which did not contain CD30 + cells. Increased numbers of CD30 + cells were more commonly seen in later stages of HIV-1 disease. However, the expression of CD30 appeared to be better in predicting other established Th2 cutaneous infiltrates in HIV-1 negative patients than in predicting a Th2 cutaneous cytokine pattern in advanced HIV-1 disease.
- Published
- 1998